Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Tilray Brands Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $299.29 (market cap $8.04B), while Tilray Brands Inc trades at $4.46 (market cap $540.74M). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 14.9× Tilray Brands Inc's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals.
| BIO | TLRY | |
|---|---|---|
Market Cap | $8.04B | $540.74M |
Sector | Health | Health |
52-Week High | $339.75 | $21.00 |
52-Week Low | $241.71 | $4.31 |
Enterprise Value | $7.85B | $637.89M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
TLRY trades at $4.46, up 0.9% on the day, amid a bearish technical signal and mixed earnings history. The company reported a net loss of $2.19 billion in 2025, with a negative net income margin of -156.67%, though revenue grew to $821.31 million. Analyst consensus is cautious with 65% hold ratings, and recent news highlights expansion in medical cannabis and new product launches.
The outlook remains challenged by persistent losses and high debt levels, but low valuation ratios like P/S of 0.54 and P/B of 0.35 may attract value investors. Key risks include profitability struggles and regulatory uncertainty, while potential catalysts include international expansion and upcoming earnings on July 28, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
